Prospects of replication-deficient adenovirus based vaccine development against SARS-CoV-2
Mariangela Garofalo , Monika Staniszewska , Stefano Salmaso , Paolo Caliceti , Katarzyna Wanda Pancer , Magdalena Wieczorek , Lukasz Kuryk
The current appearance of the new SARS coronavirus 2 (SARS-CoV-2) and it quickly spreading across the world poses a global health emergency. The serious outbreak position is affecting people worldwide and requires rapid measures to be taken by healthcare systems and governments. Vaccinations represent the most effective strategy to prevent the epidemic of the virus and to further reduce morbidity and mortality with long-lasting effects. Nevertheless, currently there are no licensed vaccines for the novel coronaviruses. Researchers and clinicians from all over the world are advancing the development of a vaccine against novel human SARS-CoV-2 using various approaches. Herein, we aim to present and discuss the progress and prospects in the field of vaccine research towards SARS-CoV-2 using adenovirus (AdV) replication deficient-based strategies, with a comprehension that may support research and combat this recent world health emergency.
|Journal series||Vaccines, ISSN 2076-393X|
|Publication size in sheets||0.5|
|Keywords in English||SARS-CoV-2; vaccine; adjuvant; adenovirus; COVID-19|
|ASJC Classification||; ; ; ;|
|Score||= 140.0, 01-07-2020, ArticleFromJournal|
|Publication indicators||= 0; : 2016 = 0.106; : 2018 = 4.76 (2)|
* presented citation count is obtained through Internet information analysis and it is close to the number calculated by the Publish or Perish system.